Disseminated Intravascular Coagulation in Sepsis

 

 Buy Article Permissions and Reprints

ABSTRACT

Disseminated intravascular coagulation (DIC) has been considered a rather rare syndrome characterized by severe bleeding. In fact, both of these beliefs are wrong. Bleeding is fairly rare in DIC. The clotting parameters are usually normal unless the DIC is fulminating. It is usually thought that fibrinogen may be low or absent in DIC. However, afibrinogenemia is rare. Fibrinogen is usually high in DIC because of the high rate of fibrinogen manufacture by the liver in response to stress. DIC is very common and most cases are never diagnosed. This is because it has been hard to find fibrin thrombi in autopsy cases and because acute severe bleeding is uncommon. The reason fibrin thrombi are rare may be because they have been lysed by endogenous fibrinolytic enzymes before the autopsy. The appearance of endogenous fibrinolytic response could be a defense mechanism to lyse the microclots of DIC. In fact, this response is often successful. This defense can be aided by the administration of plasminogen activators that will lyse the clots. Heparin has been used for the treatment of DIC but has proved useless and is, in fact, dangerous. This is because heparin will not dissolve clots and may actually promote platelet agglutination. Administration of plasminogen activators will actually prevent bleeding diathesis.

REFERENCES

• 1 Landois. Tranfusion des Blutes. Leipzig 1875
  Google Scholar
• 2 Schneider C L. Fibrin embolism with defibrination as one of the end results during placenta abruptio.  Surg Gynecol Obstet . 1951;  92 27-34
  PubMedGoogle Scholar
• 3 Hardaway R M, McKay D G, Williams J H. Lower nephron nephrosis.  Am J Surg . 1954;  87 41-49
  CrossrefPubMedGoogle Scholar
• 4 Hardaway R M. Disseminated intravascular coagulation syndromes.  Arch Surg . 1961;  83 842-850
  PubMedGoogle Scholar
• 5 Hardaway R M. Syndrome of Disseminated Intravascular Coagulation with Special Reference to Shock and Hemorrhage.  Springfield, IL: Charles C Thomas; 1966
  Google Scholar
• 6 Hardaway R M, James J M, Anderson R W. Intensive study and treatment of shock in man.  JAMA . 1967;  199 779-790
  CrossrefPubMedGoogle Scholar
• 7 Hardaway R M. A review of septic shock.  Am Surg . 2000;  66 22-29
  PubMedGoogle Scholar
• 8 Singer S N, Nicolson G L. The fluid model of the structure of cell membranes.  Science . 1972;  720 175-180
  PubMedGoogle Scholar
• 9 Schwartz R S, Chiu D TY, Lubin B. Studies on the organization of plasma membrane phospholipids in human erythrocyte. In: Kracheber WE, Eaton JW, Aston J, et al, eds. Erythrocyte Membranes, 3 Recent Chemical and Experimental Advances New York: Arliss 1984: 89-122
  Google Scholar
• 10 Chiu D, Lubin B, Shobet S B. Erythrocyte membrane lipid organization during the sickling process.  Br J Hematol . 1979;  41 223-234
  PubMedGoogle Scholar
• 11 Feola M, Simons J, Conigardo P C. Toxicity of polymerized hemoglobin solution.  Surg Gynecol Obstet . 1988;  66 211-222
  PubMedGoogle Scholar
• 12 Tuomanen E. Breaching the blood-brain barrier.  Sci Am . 1993;  80-84
  PubMedGoogle Scholar
• 13 Hardaway R M, McKay D G. Disseminated intravascular coagulation: a cause of shock.  Ann Surg . 1959;  149 462-470
  CrossrefPubMedGoogle Scholar
• 14 Hardaway R M, Johnson O. Clotting mechanism in endotoxin shock-a manifestation of DIC.  Ann Surg . 1961;  154 791-802
  PubMedGoogle Scholar
• 15 Hardaway R M, Williams C H, Yang S un. A new approach to the treatment of experimental septic shock.  J Surg Res . 1996;  61 311-316
  CrossrefPubMedGoogle Scholar
• 16 Hardaway R M, Harke H, Williams C H. Fibrinolytic agents: a new approach to the treatment of ARDS.  Adv Ther . 1994;  11 43-51
  PubMedGoogle Scholar
• 17 Hardaway R M. Traumatic and septic shock alias post-trauma critical illness.  Br J Surg . 1998;  85 1473-1479
  CrossrefPubMedGoogle Scholar
• 18 Hardaway R M. Disseminated intravascular coagulation and the treatment of ARDS with plasminogen activator.  Hematol Rev . 1994;  9 3-19
  PubMedGoogle Scholar
• 19 Hardaway R M. Treatment of ARDS.  Drugs Today . 1994;  30 645-653
  PubMedGoogle Scholar
• 20 Aiuto L T, Barone S R, Cohen P S. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans.  Crit Care Med . 1997;  25 1079-1082
  PubMedGoogle Scholar
• 21 Horne M K. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans.  Crit Care Med . 1997;  25 909 Editorial
  PubMedGoogle Scholar
• 22 Zenz W, Bodo Z, Zobel G. Recombinant tissue plasminogen activator restores perfusion in meningococcal purpura fulminans.  Crit Care Med . 1998;  25 969-971
  PubMedGoogle Scholar
• 23 Hardaway R M. Shock and disseminated intravascular coagulation. In: Hardaway RM, ed. Shock: The Reversible Stage of Dying Littleton, MA: Year Book 1988: 321-329
  Google Scholar
• 24 Hardaway R M, Johnson D G, Houchin D N. Influence of stress on fibrinogen.  J Trauma . 1964;  4 673-676
  PubMedGoogle Scholar
• 25 Hardaway R M. Mechanism of action of fibrinolysin in the prevention of irreversible hemorrhagic shock.  Ann Surg . 1963;  157 305-309
  CrossrefPubMedGoogle Scholar
• 26 Adams W H. Bleeding. In: Problems in Critical Care, Vol 3. Philadelphia: Lippincott 1989: 108-138
  Google Scholar
• 27 Hardaway R M, Drake D C. Prevention of ``irreversible'' hemorrhagic shock with fibrinogen.  Ann Surg . 1963;  157 39-47
  PubMedGoogle Scholar
• 28 Hardaway R M, Johnson D G. Influence of fibrinolysin on shock.  JAMA . 1963;  183 597-599
  PubMedGoogle Scholar
• 29 Hardaway R M, Williams C H, Marvasti M. Prevention of ARDS with plasminogen activator.  Crit Care Med . 1990;  18 1413-1418
  PubMedGoogle Scholar
• 30 Hardaway R M. Trauma sepsis and DIC.  J Intensive Care Med . 1995;  10 145-152
  PubMedGoogle Scholar